Braxia Scientific (XCNQ:BRAX) FCF Margin % : -110.16% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Braxia Scientific's Free Cash Flow for the three months ended in Dec. 2023 was C$-0.54 Mil. Braxia Scientific's Revenue for the three months ended in Dec. 2023 was C$0.49 Mil. Therefore, Braxia Scientific's FCF Margin % for the quarter that ended in Dec. 2023 was -110.16%.

As of today, Braxia Scientific's current FCF Yield % is -185.52%.

The historical rank and industry rank for Braxia Scientific's FCF Margin % or its related term are showing as below:

XCNQ:BRAX' s FCF Margin % Range Over the Past 10 Years
Min: -501.59 Med: -440.66 Max: -118.98
Current: -118.98

During the past 3 years, the highest FCF Margin % of Braxia Scientific was -118.98%. The lowest was -501.59%. And the median was -440.66%.

XCNQ:BRAX's FCF Margin % is ranked better than
52.54% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs XCNQ:BRAX: -118.98

Braxia Scientific FCF Margin % Historical Data

The historical data trend for Braxia Scientific's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific FCF Margin % Chart

Braxia Scientific Annual Data

Trend

Mar21

Mar22

Mar23

FCF Margin %

-501.59

-305.51

-440.66

Braxia Scientific Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial												-742.94	-258.43	-94.50	-28.45	-110.16

Competitive Comparison of Braxia Scientific's FCF Margin %

For the Biotechnology subindustry, Braxia Scientific's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Braxia Scientific's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Braxia Scientific's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Braxia Scientific's FCF Margin % falls into.

Braxia Scientific FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Braxia Scientific's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-8.302	/	1.884
	=	-440.66 %

Braxia Scientific's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.542	/	0.492
	=	-110.16 %

Braxia Scientific FCF Margin % Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Braxia Scientific (XCNQ:BRAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BRAXF:USA 4960:Germany

Address

700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6

Website

https://www.braxiascientific.com

Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines